Navigation Links
Resistance to anti-HIV drugs in Uganda developed due to drug supply problems

Some HIV-infected patients in Uganda who self-paid for their antiretroviral medications experienced interruptions in drug supply due to either financial demands or supply logistical disruptions. These treatment interruptions led to the development of resistance to antiretroviral medications in patients.

These findings by a team led by researchers at the Infectious Diseases Institute at Makerere University, Kampala, and UCSF are reported in the April 22, 2007 issue of the journal "AIDS."

"We have found the concern is not about the occasional missed dose—most of the patients had near perfect adherence and full suppression of the virus?but about supply interruptions that led to longer multi-day treatment interruptions allowing resistance to develop," said study lead author Jessica Oyugi, MD, from the Infectious Diseases Institute at Makerere University, Kampala, Uganda.

The study followed just under 100 patients who self paid for generic fixed-dose antiretroviral formulations. Findings showed that medications were very effective at suppressing the virus, with full viral suppression in over 80 percent of people on treatment for 6 months. Resistance developed in people during treatment interruptions, and 90 percent of all missed doses were due to treatment interruptions as opposed to the occasional skipped dose. Further, almost 50 percent of the participants interrupted treatment due to financial difficulties. In addition, at one point during the study period, supply of one product was halted due to customs issues. A two-week nationwide shortage resulted that created gaps in treatment for some individuals taking that medication.

"In a context where the ability of poor people to adhere to medications regimens has been questioned, the issue is not so much about behavioral strategies to increase adherence, but about structural failures that interrupt access to treatment. Free access to treatment leads to better survival than self-pay therapy because free treatment may be less susceptible to interruptions that lead to resistance" said study senior author David R. Bangsberg, MD, MPH, director of the UCSF Epidemiology and Prevention Interventions Center at San Francisco General Hospital.

The climate in Uganda has changed since the study took place between September 2002 and April 2004. At that time, most patients paid for antiretroviral therapy. Today, most HIV patients are receiving drugs supplied for free by either PEPFAR—the U.S. President’s Emergency Plan for AIDS Relief, a five-year, $15-billion, multifaceted approach to combating HIV/AIDS around the world—or The Global Fund to Fight AIDS, Tuberculosis and Malaria, which was created to dramatically increase resources to fight three of the world's most devastating diseases, and to direct those resources to areas of greatest need.

"Notwithstanding the current programs providing free antiretrovirals, these findings do highlight the need for strong logistics and drug supply management in any antiretroviral therapy program as well as continued monitoring of adherence. While our patients did a great job of taking their medications as directed when they were affordable and available, their overall adherence did wane a bit over the study period," said Oyugi.
'"/>

Source:University of California - San Francisco


Related biology news :

1. To Stop Evolution: New Way Of Fighting Antibiotic Resistance Demonstrated By Scripps Scientists
2. Large-scale Computer Simulations Reveal New Insights Into Antibiotic Resistance
3. Resistance and genetic sensitivity to sleeping sickness
4. Living anti-HIV gel shows early promise
5. Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G
6. Molecular machine may lead to new drugs to combat human diseases
7. Researchers identify target for cancer drugs
8. MetaChip provides quick, efficient toxicity screening of potential drugs
9. Newly discovered pathway might help in design of cancer drugs
10. UNC launches study of liver injury caused by drugs
11. Findings have implications for tracking disease, drugs at the molecular level

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2017)... , Feb. 9, 2017 The biomass ... analysis of the biomass boiler market globally in terms ... of biomass boilers. The market for biomass boilers has ... type, end-user, application, and country/region. The market based on ... & forest residues, biogas & energy crops, urban residues, ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... a leading digital health company, and Digital ... telemedicine and remote patient monitoring, announce they are ... DN Telehealth maximizes collaboration compatibility ... extending consultations beyond a physical clinical setting to ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... The ... announce a new partnership with Compass Research . GGI's mission is to advance ... vaccine to a child in need in honor of each clinical trial volunteer. The ...
Breaking Biology Technology: